786666-11-3Relevant articles and documents
Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists
Gao, Zhan-Guo,Duong, Heng T.,Sonina, Tatiana,Kim, Soo-Kyung,Van Rompaey, Philippe,Van Calenbergh, Serge,Mamedova, Liaman,Kim, Hea Ok,Kim, Myong Jung,Kim, Ae Yil,Liang, Bruce T.,Jeong, Lak Shin,Jacobson, Kenneth A.
, p. 2689 - 2702 (2007/10/03)
An alternative approach to overcome the inherent lack of specificity of conventional agonist therapy can be the reengineering of the GPCRs and their agonists. A reengineered receptor (neoceptor) could be selectively activated by a modified agonist, but no